China Biotech Services Holdings (HKSE:08037) GF Value Rank: 1 (As of Aug. 21, 2026) — 50% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:08037 China Biotech Services Holdings Ltd HKSE:08037
29 GF Score
Price HK$0.62
GF Value HK$0.26
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is China Biotech Services Holdings GF Value Rank?

China Biotech Services Holdings HKSE:08037 +0.81% 29 GF Value Rank is 1 as of Aug. 21, 2026, which is 50% below its 10-year median of 2.00. GuruFocus rates HKSE:08037 with a GF Score™ of 29/100 and a GF Value™ of HK$0.26 (Significantly Overvalued). The stock has 6 warning signs investors should review.

China Biotech Services Holdings has the GF Value Rank of 1.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


China Biotech Services Holdings GF Value Rank Related Terms


HKSE:08037 vs TMO, DHR, IDXX: GF Value Rank Comparison

For the Diagnostics & Research subindustry, China Biotech Services Holdings's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Biotech Services Holdings GF Value Rank vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, China Biotech Services Holdings's GF Value Rank distribution charts can be found below:

* The bar in red indicates where China Biotech Services Holdings's GF Value Rank falls into.


HKSE:08037
29GF Score
China Biotech Services Holdings Ltd HKSE:08037
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 1 mean?
China Biotech Services Holdings (HKSE:08037) has a GF Value Rank of 1 as of Aug. 21, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on China Biotech Services Holdings and its competitors. This is 50% below median its historical median of 2.00. Over the past decade, China Biotech Services Holdings' GF Value Rank has ranged from 1.00 to 10.00.
Is China Biotech Services Holdings' GF Value Rank too high?
China Biotech Services Holdings' current GF Value Rank of 1 is 50% below median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, China Biotech Services Holdings has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Biotech Services Holdings' GF Value Rank compare to TMO and DHR?
China Biotech Services Holdings' GF Value Rank of 1 can be compared against companies in the Medical Diagnostics & Research industry. Historically, China Biotech Services Holdings' own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Medical Diagnostics & Research company?
A good GF Value Rank depends on the Medical Diagnostics & Research industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on China Biotech Services Holdings and its competitors. China Biotech Services Holdings's current GF Value Rank is 1, which is 50% below median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Biotech Services Holdings stock overvalued right now?
Based on GuruFocus' analysis, China Biotech Services Holdings (HKSE:08037) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.26, compared to a current price of HK$0.62 — trading 138.5% above its estimated fair value. The current GF Value Rank is 1, which is 50% below median its 10-year median of 2.00. China Biotech Services Holdings' overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For China Biotech Services Holdings (HKSE:08037), the current GF Value Rank is 1 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China Biotech Services Holdings (HKSE:08037) Overvalued in 2026?

Based on GuruFocus' analysis, China Biotech Services Holdings stock appears to be overvalued. The current stock price of HK$0.62 is trading 138.5% above its estimated GF Value™ of HK$0.26. GuruFocus considers China Biotech Services Holdings to be Significantly Overvalued.

Key valuation signals for HKSE:08037:

  • GF Value Rank: 1 (50% below median its 10-year median of 2.00)
  • GF Value™: HK$0.26 vs. price of HK$0.62 (138.5% above fair value)
  • GF Score™: 29/100 with 6 warning signs

No single metric tells the full story. See the HKSE:08037 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


China Biotech Services Holdings Business Description

Address 255-257 Gloucester Road, Suites 1904-05A, 19th Floor, Sino Plaza, Causeway Bay, Hong Kong, HKG
China Biotech Services Holdings Ltd is an investment holding company. It operates through five segments: Pharmaceutical Products, Medical and Health-Related Services, Immunotherapy, Insurance brokerage, BNCT, and Others. It derives prime revenue from the Medical & health-related services segment, which involves the provision of medical laboratory testing & health check services. The group has a business presence in Hong Kong & the PRC, of which key revenue is generated from Hong Kong. Immunotherapy-provision of tumor immune cell therapy & health management services. Pharmaceutical products-sale & distribution of health-related & pharmaceutical products. Insurance brokerage services. BNCT-provision of boron neutron capture therapy treatment services, & Others-provision of logistic services.
29GF Score

Get the complete analysis for HKSE:08037

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.62
Price
HK$0.26
GF Value